PT-141 (Bremelanotide)

PT-141, also known as Bremelanotide, is a synthetic peptide originally developed from Melanotan II. Unlike traditional treatments, PT-141 works by directly activating receptors in the brain that influence sexual desire. It has been FDA-approved for treating low sexual desire in women and is also studied for its potential benefits in both men and women.

PT-141 (Bremelanotide) is FDA-approved for HSDD in women but is still considered investigational for other uses. This information is provided for research and educational purposes only.

What is PT-141 (Bremelanotide)?

PT-141, also known as Bremelanotide, is a synthetic peptide that activates melanocortin receptors, primarily MC3R and MC4R, in the central nervous system. It is a derivative of Melanotan II, but unlike its parent compound, PT-141 does not significantly affect skin pigmentation. Instead, it is researched and FDA-approved for its role in enhancing sexual desire and arousal, particularly in women.

Potential Benefits Shown in Studies

Increasing sexual arousal and libido
Improving erectile function in men
Enhancing sexual desire in premenopausal women
Acting on the central nervous system (not hormones)
Offering benefits without significantly affecting blood pressure or hormones
Working independently of testosterone or estrogen levels

Mechanisms of Action

PT-141 acts directly on the nervous system, not the vascular system, which differentiates it from drugs like Viagra or Cialis. It works by:

Stimulating melanocortin receptors in the brain, enhancing libido
Increasing sexual arousal by acting on MC4R (linked to arousal and motivation)
Bypassing hormonal pathways, offering effects even in low-testosterone states
Triggering natural physiological responses associated with sexual readiness

Research Highlights

FDA Approval for Hypoactive Sexual Desire Disorder (HSDD)

PT‑141 (marketed as Vyleesi) received FDA approval in 2019 for treating acquired, generalized HSDD in premenopausal women, offering an as-needed treatment for low desire.

Source: Mayo Clinic

Central Nervous System Mechanism via Melanocortin Receptors

Bremelanotide acts centrally by activating melanocortin receptors—chiefly MC3R and MC4R—in the brain to directly enhance sexual desire and arousal, distinct from vascular-centric treatments.

Source: wikipedia

Clinical Evidence of Efficacy in Human Trials

Phase III clinical trials have demonstrated that Bremelanotide increases sexual desire scores and reduces related psychological distress compared to placebo in women with HSDD.

Source: Functional Medicine

Neurobehavioral Impact Documented via fMRI Study

An fMRI-based, double-blind, crossover clinical study found that Bremelanotide alters brain activity—damping self-consciousness while enhancing erotic sensitivity and positive response in women with HSDD.

Source: academic.oup